{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:04:01Z","timestamp":1771430641068,"version":"3.50.1"},"reference-count":19,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,1,23]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Systemic sclerosis (SSc) is a rare autoimmune disease characterised by skin and organ fibrosis, vasculopathy and immune dysregulation. Given the disease heterogeneity and severity, accurate prognostic and predictive markers are needed. Blood immunophenotyping by flow or mass cytometry offers a promising non-invasive approach to identify immune signatures associated with disease subtypes, complications (eg, interstitial lung disease, scleroderma renal crisis, digital ulcers) and treatment responses. However, findings remain inconsistent and lack clinical standardisation. This systematic review aims to identify cytometry-based blood immune markers associated with clinical outcomes in SSc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A comprehensive search will be conducted on three databases: PubMed, Web of Science and Cochrane Library, from their inception to the date of the final search (21 December 2025). Data will be extracted and analysed using a predefined charting form. Studies published in English or French reporting the use of flow or mass cytometry for peripheral blood cells phenotyping in adults with SSc will be included. Comparators will include healthy controls, other autoimmune diseases, disease severity groups and treatment response subgroups. The primary outcome will be the association with the diffuse cutaneous subtype, while secondary outcomes will include overall survival and disease-specific mortality, organ involvement, progression of the disease and treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval is not required as this review is an analysis of published scientific literature and does not involve patients. The results of this systematic literature review will be submitted for publication in a peer-reviewed journal and presented at relevant conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration<\/jats:title>\n                    <jats:p>CRD420250644594.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-115864","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:10:44Z","timestamp":1771427444000},"page":"e115864","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Cytometry-based blood immune cell markers associated with clinical outcomes in systemic sclerosis: protocol for a systematic review"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9226-0558","authenticated-orcid":false,"given":"Marion","family":"Souffez","sequence":"first","affiliation":[{"name":"P\u00f4le Biologie, CHU Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2438-7735","authenticated-orcid":false,"given":"Erwan","family":"Dumontet","sequence":"additional","affiliation":[{"name":"P\u00f4le Biologie, CHU Rennes, Rennes, France"},{"name":"UMR 1236, Universit\u00e9 Rennes, INSERM, \u00c9tablissement Fran\u00e7ais du Sang Bretagne, \u00c9quipe Labellis\u00e9e Ligue Contre le Cancer, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8606-4755","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Lecureur","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sant\u00e9, environnement et travail) \u2013 UMR_S 1085, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2081-8558","authenticated-orcid":false,"given":"Alain","family":"Lescoat","sequence":"additional","affiliation":[{"name":"Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en sant\u00e9, environnement et travail) \u2013 UMR_S 1085, Rennes, France"},{"name":"Department of Internal Medicine and Clinical Immunology, CHU Rennes, Univ Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2193-4104","authenticated-orcid":false,"given":"Juliette","family":"Ferrant","sequence":"additional","affiliation":[{"name":"P\u00f4le Biologie, CHU Rennes, Rennes, France"},{"name":"UMR 1236, Universit\u00e9 Rennes, INSERM, \u00c9tablissement Fran\u00e7ais du Sang Bretagne, \u00c9quipe Labellis\u00e9e Ligue Contre le Cancer, Rennes, France"},{"name":"SITI, CHU Rennes, \u00c9tablissement Fran\u00e7ais du Sang Bretagne, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2026021807101847000_16.2.e115864.1","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"The Lancet"},{"key":"2026021807101847000_16.2.e115864.2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2023.1729","article-title":"Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database","volume":"159","author":"Lescoat","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2026021807101847000_16.2.e115864.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"2026021807101847000_16.2.e115864.4","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00244-7"},{"key":"2026021807101847000_16.2.e115864.5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/23971983221129211","article-title":"Very Early Diagnosis of Systemic Sclerosis: Deciphering the heterogeneity of systemic sclerosis in the very early stages of the disease","volume":"8","author":"Lescoat","year":"2023","journal-title":"J Scleroderma Relat Disord"},{"key":"2026021807101847000_16.2.e115864.6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12016-021-08891-0","article-title":"Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies","volume":"64","author":"Lescoat","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026021807101847000_16.2.e115864.7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers","volume":"64","author":"Cavazzana","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026021807101847000_16.2.e115864.8","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15145","article-title":"Alterations in peripheral T- and B-cell subsets in patients with systemic sclerosis","volume":"27","author":"Wu","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"2026021807101847000_16.2.e115864.9","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8505-8"},{"key":"2026021807101847000_16.2.e115864.10","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s10067-017-3597-6","article-title":"CD16-positive circulating monocytes and fibrotic manifestations of systemic sclerosis","volume":"36","author":"Lescoat","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2026021807101847000_16.2.e115864.11","doi-asserted-by":"crossref","first-page":"1376933","DOI":"10.3389\/fimmu.2024.1376933","article-title":"Comparative single-cell multiplex immunophenotyping of therapy-naive patients with rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus shed light on disease-specific composition of the peripheral immune system","volume":"15","author":"Balog","year":"2024","journal-title":"Front Immunol"},{"key":"2026021807101847000_16.2.e115864.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217116"},{"key":"2026021807101847000_16.2.e115864.13","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1093\/rheumatology\/keaf198","article-title":"T cells of patients with systemic sclerosis or Sj\u00f6gren\u2019s disease display an aberrant metabolic state and memory phenotype in blood and lungs","volume":"64","author":"Ehlers","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026021807101847000_16.2.e115864.14","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1038\/s41598-025-89238-z","article-title":"Natural killer cells are decreased in systemic sclerosis and have diagnostic value for pulmonary arterial hypertension incorporation","volume":"15","author":"Guo","year":"2025","journal-title":"Sci Rep"},{"key":"2026021807101847000_16.2.e115864.15","unstructured":"Higgins JPT , Thomas J , Chandler J , et al ., eds. Cochrane handbook for systematic reviews of interventions version 6.5 (updated august 2024). Cochrane, 2024."},{"key":"2026021807101847000_16.2.e115864.16","unstructured":"Wells GA , Shea B , O\u2019Connell D , et al . The newcastle-ottawa scale (nos) for assessing the quality of nonrandomized studies in meta-analyses. 2010. Available: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/ oxford.htm [Accessed 2 Mar 2010]."},{"key":"2026021807101847000_16.2.e115864.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026021807101847000_16.2.e115864.18","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2026021807101847000_16.2.e115864.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.05.010"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-115864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T15:10:47Z","timestamp":1771427447000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-115864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,18]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2025-115864"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-115864","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}